Cargando…
S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
BACKGROUND: Lurasidone is once a day oral medication, which could be administered any time of the day, but the relationship between the timing of administration and the risk of developing adverse events has not been systematically evaluated. The purpose of this study was to examine whether there is...
Autores principales: | Hagi, Katsuhiko, Tadashi, Nosaka, Pikalov, Andrei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234044/ http://dx.doi.org/10.1093/schbul/sbaa031.071 |
Ejemplares similares
-
M48. IS METABOLIC SYNDROME RELATED TO COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA? RESULTS FROM A DOUBLE-BLIND, ACTIVE-CONTROLLED, LURASIDONE STUDY
por: Hagi, Katsuhiko, et al.
Publicado: (2020) -
T28. BENEFITS AND HARMS OF ANTIPSYCHOTICS IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2020) -
S212. LONG-TERM CHANGES OF MIRNA30A FOLLOWING EXPOSURE TO PRENATAL STRESS: MODULATORY EFFECTS OF LURASIDONE TREATMENT DURING ADOLESCENCE
por: Cattaneo, Annamaria, et al.
Publicado: (2020) -
Timing of COVID-19 as a Predictor of Adverse Neonatal Outcomes
por: Mussarat, Naiha, et al.
Publicado: (2022) -
S179. ADMINISTRATION OF ROTENONE DURING NEONATAL PERIOD INDUCES SCHIZOPHRENIA-LIKE BEHAVIOR
por: Siena, Amanda, et al.
Publicado: (2020)